Last update: Sat Oct 14 02:05:31 MDT 2023
@Book{Crowley:2006:HSC,
editor = "John Crowley and Donna Pauler Ankerst",
title = "Handbook of Statistics in Clinical Oncology",
publisher = "Chapman and Hall/CRC",
address = "Boca Raton, FL, USA",
edition = "Second",
pages = "617",
year = "2006",
ISBN = "0-8247-2339-2",
ISBN-13 = "978-0-8247-2339-2",
LCCN = "RC267 .H36 2006",
MRclass = "62P10, 62-00, 92-00, 92C50",
bibdate = "Wed Mar 5 08:40:05 MST 2014",
bibsource = "fsz3950.oclc.org:210/WorldCat;
https://www.math.utah.edu/pub/tex/bib/japplstat.bib",
URL = "http://catdir.loc.gov/catdir/enhancements/fy0648/2006273842-d.html;
http://catdir.loc.gov/catdir/toc/fy0606/2006273842.html;
http://www.zentralblatt-math.org/zmath/en/search/?an=1140.62347",
acknowledgement = ack-nhfb,
subject = "Cancer; Research; Statistical methods; Clinical
trials; Recherche; M{\'e}thodes statistiques;
{\'E}tudes cliniques; Neoplasms; therapy; Research
Design; Clinical Trials as Topic; Computational
Biology; Data Interpretation, Statistical; Statistical
methods.",
tableofcontents = "Overview of phase I trials \\
Phase I and phase I/II dose finding algorithms using
continual reassessment method \\
Choosing a phase I design \\
Pharmacokinetics in clinical oncology: statistical
issues \\
Practical implementation of the continual reassessment
method \\
Overview of Phase II clinical trials \\
Designs based on toxicity and response \\
Phase II trials using time-to-event endpoints \\
Phase II selection designs \\
On use of covariates in randomization and analysis of
clinical trials \\
Factorial designs with time to event endpoints \\
Noninferiority trials \\
Power and sample size for phase III clinical trials of
survival \\
Early stopping of cancer clinical trials \\
Design and analysis of quality of life data \\
Economic analyses alongside cancer clinical trials \\
Prognostic factor studies \\
Statistical methods to identify predictive factors \\
Explained variation in proportional hazards regression
\\
Constructing prognostic groups by tree-based
partitioning and peeling methods \\
Clinical monitoring based on joint models for
longitudinal biomarkers and event times \\
Some practical considerations for analysis of spotted
microarray data \\
Statistical applications using DNA microarrays for
cancer diagnosis and prognosis \\
Profiling high-dimensional protein expression using
MALDI-TOF: mass spectrometry for biomarker discovery
\\
Statistical approaches for high dimensional data
derived from high throughput assays: a case study of
protein expression levels in lung cancer \\
Spatial modeling of multilocus data \\
Software for genomic data \\
Bayesian sensitivity analyses of confounded treatment
effects \\
Interpreting longitudinal studies of QOL with
nonignorable dropout \\
Estimation of cumulative incidence in the presence of
competing risks \\
Pitfalls in the design, conduct and analysis of
randomized clinical trials \\
Dose-intensity analysis \\
Sequential randomization",
}